1Nekarda H, Schmitt M. Ulm K. et al. Prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res, 1994,54(11):2900-2907.
2Nagayama M. Sato A, Hayakawa H. et al. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer, 1994.73(5) : 1398-1405.
3Kluft C, Verheijen JH. Leiden fibrinolysis working party: blood collection and handling procedure for assessment of tissue type plasminogen (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis,1990.4(Suppl 2) : 155.
4Brambilla C, Brambilla E. Fundamental biology and clinical management. In: Lenfant C ed. Lung tumors. New York: Marcel Dekker Inc,1999.269-277.
5Heidtmann HH, Hofmann M, Jacob E, et al. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res,1989,49(24 Pt 1) : 6960-6965.
6Salden M, Splinter TA, Peters HA, et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol,2000,11(3):327-332.
8Kristensen P, Pyke C, Lund LR, et al. Plasminogen activator inhibitor type 1 in Lewis lung carcinoma. Histochemistry, 1990, 93(6) : 559-566.
9Montemurro P, Conese M, Ahomare DF, et al. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. Int J Clin Lab Res, 1995,25(4) : 195-200.
10Kirchheimer JC, Huber K, Wagner O, et al. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol,1987,66(1):85-89.
3Pinson P,Joos G,Watripont P,et al.Serum neuronspecific enolase as a tumor marker in the diagnosis and followup of small-cell lung cancer[J].Respiration,1997,64(1):102-107.
4Plebani M,Basso D,Navaglia F,et al.Clinical evaluation of seven tumor markers in lung cancer diagnosis;can any combination improve the results[J].Br J Cancer,1995,72(3):170-173.
5Robert C,Bolon I,Gazzeri S,et al.Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression[J].Clin Cancer Res,1999,5(8):2094-2102.
6Bolon I,Devouassoux M,Robert C,et al.Expression of urokinase-type plasminogen activator,stromelysin 1,stromelysin 3 and matrilysin genes in lung carcinomas[J].Am J Pathol,1997,150(5):1619-1629.
7Shetty S,Idell S.Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro[J].Am J Physiol Lung Cell Mol Physiol,2000,278(1):L148-L156.
8Kristensen P,Pyke C,Lund LR,et al.Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma[J].Histochemistry,1990,93(6):559-566.
9吴一龙.肿瘤多学科综合治疗的理论与实践[M].北京:人民卫生出版社,2000.295-296.
10Kulpa J, WOjcik E, Radkowski A, et al. CYFRA 21-1, TPA-M TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res, 2000, 20:5035-5040.
